Sugi Predict

Sugi Predict / Compounds / SCHEMBL1592867

SCHEMBL1592867

SCHEMBL1592867

Oc1n[nH]c2ncc(Br)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1B Q9Y463 12/20 0.44
▸ DYRK1A Q13627 10/20 0.44
▸ AURKA O14965 3/20 0.44
▸ JAK2 O60674 3/20 0.44
▸ MAP4K4 O95819 3/20 0.44
▸ FGFR1 P11362 3/20 0.44
▸ FLT1 P17948 3/20 0.44
▸ KDR P35968 3/20 0.44
▸ CLK2 P49760 3/20 0.44
▸ CDK5 Q00535 3/20 0.44
▸ MAP4K2 Q12851 3/20 0.44
▸ AURKB Q96GD4 3/20 0.44
▸ CLK4 Q9HAZ1 3/20 0.44
▸ DAPK3 O43293 2/20 0.44
▸ PAK4 O96013 2/20 0.44
▸ ABL1 P00519 2/20 0.44
▸ RET P07949 2/20 0.44
▸ PDGFRA P16234 2/20 0.44
▸ LTK P29376 2/20 0.44
▸ GRK5 P34947 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1585071 0.78 DYRK1A (0.55) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL30508312 0.78 DYRK1A (0.55) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL12831912 0.77 DYRK1A (0.35) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL29872842 0.77 JAK2 (0.39) JAK2ROCK1GSK3AGSK3BIDO1
SCHEMBL1585882 0.77 DYRK1B (0.44) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL16537147 0.77 DYRK1B (0.44) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL1144888 0.77 DYRK1B (0.44) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL1585445 0.77 DYRK1B (0.41) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL29930770 0.76 DYRK1B (0.58) DYRK1BDYRK1AAURKAJAK2MAP4K4
SCHEMBL3373929 0.76 DYRK1B (0.43) DYRK1BDYRK1AAURKAJAK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306640-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-09-29 — — US disclosed
EP-3430005-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE PLEXXIKON INC (US) 2021-12-08 — — EP disclosed
EP-3430005-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE Plexxikon Inc. (US) 2019-01-23 — — EP disclosed
US-10160747-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2018-12-25 — — US disclosed
US-20170267660-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2017-09-21 — — US disclosed
US-20170267660-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2017-09-21 — — US disclosed
WO-2017161045-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE PLEXXIKON INC. (US) 2017-09-21 — — WO disclosed
WO-2017161045-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS THEREFORE PLEXXIKON INC. (US) 2017-09-21 — — WO disclosed
US-9725465-B2 Biaryl acetamide compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-08 — — US disclosed
EP-3039021-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2016-07-06 — — EP disclosed
US-20140249170-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS KUMAR, AJAY, DR. (GB) 2014-09-04 — — US disclosed
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 — — US disclosed
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 — — US disclosed
US-8394795-B2 Pyrazole [3, 4-B] pyridine Raf inhibitors ARRAY BIOPHARMA INC. (US) 2013-03-12 — — US disclosed
EP-2265610-B1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-12-12 — — EP disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 — — US disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 — — US disclosed
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-04-21 — — US disclosed
EP-2265610-A1 PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 — — EP disclosed
WO-2009111279-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267660-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PRKAR2B, AKT3, MAP3K11 DYRK1B 362/4885DYRK1A 400/4885AURKA 389/4885
US-20110092479-A1 PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS BRAF, RAF1, ARAF DYRK1B 472/4885DYRK1A 626/4885AURKA 887/4885
US-20220306640-A1 HYDANTOIN DERIVATIVE DDR1, DDR2, DDRGK1 DYRK1B 2051/4885DYRK1A 1862/4885AURKA 1135/4885
US-20140249170-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS FASN, DBI, FAAH DYRK1B 4604/4885DYRK1A 4500/4885AURKA 3774/4885
US-10160747-B2 Compounds and methods for kinase modulation, and indications therefor PRKAR2B, AKT3, MAP3K11 DYRK1B 362/4885DYRK1A 400/4885AURKA 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.